Could this startup have the cure for obesity? Meet Pep2Tango Therapeutics!

Pallavi Madhiraju- November 23, 2024

Versant Ventures has introduced Pep2Tango Therapeutics Inc., a biotechnology startup dedicated to pioneering next-generation therapies for weight loss. The company has secured significant, albeit undisclosed, ... Read More

Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges

Pallavi Madhiraju- September 20, 2024

Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More

Terns Pharmaceuticals faces market pressure following stock offering announcement

Pallavi Madhiraju- September 11, 2024

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases such as oncology and obesity, has seen a significant decline in ... Read More

Quotient Sciences opens new $15m facility in Garnet Valley to boost drug development capabilities

pharmanewsdaily- October 18, 2018

Quotient Sciences, a UK-based drug development services provider, has inaugurated a new early phase formulation and manufacturing plant in Garnet Valley, Pennsylvania. The facility, spanning ... Read More

Taro Pharmaceutical ends licensing agreement with NovaBiotics over Novexatin failure

pharmanewsdaily- September 29, 2018

Taro Pharmaceutical Industries has terminated its licensing agreement with Scottish biotech company NovaBiotics concerning the Novexatin drug after disappointing clinical trial results. The decision follows ... Read More

Tolero Pharmaceuticals and AbbVie collaborate to advance AML treatment

pharmanewsdaily- August 19, 2018

Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie to explore the potential of combining their respective drugs, alvocidib and venetoclax, for the ... Read More

Charles River Laboratories to acquire MPI Research for $800m

pallavi123- February 14, 2018

In a strategic move to bolster its position in the pharmaceutical research sector, Charles River Laboratories International, Inc. has agreed to acquire Michigan-based non-clinical contract ... Read More

Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial

pharmanewsdaily- February 26, 2017

Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not meet the primary endpoint in the pivotal ... Read More